Compare Bristol-Myers Squibb Co (BMY) vs Suncor Energy Inc. (SU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Suncor Energy Inc. — how do they compare? Bristol-Myers Squibb Co trades at $58.65 (market cap $116.30B), while Suncor Energy Inc. trades at $60.46 (market cap $71.44B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | SU | |
|---|---|---|
Market Cap | $116.30B | $71.44B |
Sector | Health | Energy |
52-Week High | $62.37 | $69.73 |
52-Week Low | $42.60 | $38.17 |
Enterprise Value | $152.24B | $79.57B |
Dividend Yield | 4.42% | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Suncor Energy (SU) trades at $61.27, up 3.41% with strong bullish momentum. The stock shows robust fundamentals with a P/E of 16.54, net margin of 11.62%, and consistent dividend payments. Recent earnings beat expectations in Q3 and Q4 2025, though Q1 2026 slightly missed. Technical indicators signal bullish sentiment with the current price near resistance at $62. Analyst consensus is strongly positive with 74% buy ratings.
SU presents a compelling investment case with attractive valuation metrics and strong profitability. However, investors face risks from oil price volatility and recent operational challenges. The company's disciplined capital allocation and record production support long-term value, but macroeconomic headwinds and competitive pressures require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
